Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vsobservation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study

Table 4 Incremental cost-effectiveness ratio (ICER, expressed in euros per QALY), of the different patient subgroups

Group	Gemcitabine (n = 154)	Erlotinib (n = 155)
All patients	76,625	184,733
Performance-status
0	52,213	94,908
1	372,624	–*
Histology
Adenocarcinoma	62,292	97,160
Squamous cell carcinoma or unknown	83,291	–*
Response to induction therapy
Objective response	64,296	101,186
Stable disease	153,337	–*

Incremental cost-effectiveness ratios (ICER) are expressed in euros/quality adjusted-life years (QALY).
*The ICER was not calculated because the tested strategy does not appear to be more effective than observation.

ISSN: 1471-2407